IRIS
PEROSA, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.541
EU - Europa 5.134
AS - Asia 4.902
SA - Sud America 1.331
AF - Africa 190
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 9
Totale 22.126
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.366
SG - Singapore 2.112
IT - Italia 1.674
CN - Cina 1.082
RU - Federazione Russa 1.056
BR - Brasile 1.051
HK - Hong Kong 647
SE - Svezia 531
DE - Germania 398
UA - Ucraina 394
VN - Vietnam 310
FI - Finlandia 304
FR - Francia 293
GB - Regno Unito 225
IN - India 148
BD - Bangladesh 139
AR - Argentina 106
CA - Canada 70
ID - Indonesia 70
IQ - Iraq 62
TR - Turchia 62
EC - Ecuador 50
MX - Messico 46
ZA - Sudafrica 40
PL - Polonia 39
JP - Giappone 37
IE - Irlanda 35
CO - Colombia 33
NL - Olanda 33
UZ - Uzbekistan 32
PK - Pakistan 30
BE - Belgio 29
CI - Costa d'Avorio 29
MA - Marocco 28
ES - Italia 27
SA - Arabia Saudita 27
CL - Cile 25
AT - Austria 24
PH - Filippine 23
VE - Venezuela 22
JO - Giordania 19
TN - Tunisia 19
PY - Paraguay 17
AU - Australia 15
KE - Kenya 15
MY - Malesia 13
CR - Costa Rica 12
EG - Egitto 12
PE - Perù 12
AZ - Azerbaigian 11
DO - Repubblica Dominicana 11
DZ - Algeria 11
IR - Iran 11
RO - Romania 10
LT - Lituania 9
PS - Palestinian Territory 9
AL - Albania 8
HR - Croazia 8
EU - Europa 7
JM - Giamaica 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
BO - Bolivia 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
KG - Kirghizistan 5
NP - Nepal 5
PA - Panama 5
RS - Serbia 5
TH - Thailandia 5
AO - Angola 4
ET - Etiopia 4
IL - Israele 4
KR - Corea 4
LB - Libano 4
MD - Moldavia 4
MK - Macedonia 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
SN - Senegal 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BB - Barbados 3
CZ - Repubblica Ceca 3
HN - Honduras 3
OM - Oman 3
PT - Portogallo 3
SV - El Salvador 3
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
BZ - Belize 2
CG - Congo 2
DK - Danimarca 2
GE - Georgia 2
GH - Ghana 2
GR - Grecia 2
GT - Guatemala 2
KH - Cambogia 2
KZ - Kazakistan 2
PR - Porto Rico 2
Totale 22.089
Salva come PNG Salva come JPEG
Città #
Singapore 1.136
Ashburn 935
Chandler 927
Jacksonville 916
Fairfield 859
Woodbridge 663
Hong Kong 641
San Jose 586
Milan 576
Houston 510
Ann Arbor 396
Nyköping 377
Seattle 359
Cambridge 354
Wilmington 324
Bari 319
Beijing 285
Rome 227
Lawrence 201
Roxbury 200
Nanjing 196
Lauterbourg 191
New York 181
Boardman 143
Los Angeles 135
Des Moines 133
Helsinki 110
Dallas 95
Ho Chi Minh City 95
Princeton 91
São Paulo 77
Santa Clara 75
Hanoi 69
Inglewood 66
Brooklyn 63
Columbus 61
Buffalo 59
Nanchang 55
Shenyang 50
London 49
Hebei 47
Chicago 44
Moscow 42
San Diego 41
Rio de Janeiro 39
Munich 37
Pune 37
Tokyo 36
Falkenstein 35
Orem 33
Turin 33
Jiaxing 32
Figino 31
Jakarta 30
Abidjan 29
Council Bluffs 29
Dublin 28
Tashkent 28
Tianjin 28
Brussels 27
Frankfurt am Main 27
Montreal 27
Belo Horizonte 26
Changsha 26
Paris 25
Warsaw 24
Atlanta 23
Guangzhou 23
Chennai 22
Denver 22
Quito 22
Stockholm 22
Amsterdam 21
Baghdad 21
Curitiba 21
Naples 21
Nuremberg 21
Dhaka 20
Noicattaro 19
Boston 18
Johannesburg 18
Amman 17
Brasília 17
Haiphong 17
Poplar 17
Porto Alegre 17
Toronto 17
Washington 17
Dong Ket 16
San Francisco 16
Dearborn 15
Marseille 15
Medellín 15
Mexico City 15
Vienna 15
Bologna 14
Campinas 14
Falls Church 14
Guayaquil 14
Buenos Aires 13
Totale 14.235
Salva come PNG Salva come JPEG
Nome #
Response to "Is active acid sphingomyelinase required for the antiproliferative response to rituximab?" [e-letter]. http://bloodjournal.hematologylibrary.org/content/117/13/3695.citation/reply#bloodjournal_el_2268 766
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 223
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading 198
Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis 187
Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis 179
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 178
Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections 175
MHC Class i Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells 171
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic 169
Autoantibodies to intracellular antigens: generation and pathogenetic role 169
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 169
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases 167
Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma 164
Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 161
AB0695 Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension 158
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 154
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis 150
CD20 mimicry by a mAb rituximab-specific linear peptide: A potential tool for active immunotherapy of autoimmune diseases 150
Antiphospholipids syndrome complicated by a systemic capillary leak-like syndrome treated with steroids and intravenous immunoglobulins a case report 149
Absence of streptococcal protein G (PG)-specific determinant in the Fab region of human IgG2 145
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? 144
Rheumatic disorders as paraneoplastic syndromes 142
Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype 141
Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature 141
Vasculitides: Proposal for an integrated nomenclature 138
CD20: A target antigen for immunotherapy of autoimmune diseases 137
Serological methods to detect anti-idiotypic antibodies 135
Effects of Adjuvants for Human Use in Systemic Lupus Erythematosus (Sle)-Prone (Nzb/Nzw) F1 Mice 135
Human CD4 internal antigen anti-idiotypic monoclonal antibody. Immunochemical and sequence analysis 134
Extra-articular manifestations of rheumatoid arthritis: an update 134
Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma 134
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 132
Alternative splicing of HLA-C mRNA in HCV-infected hepatocytes reduces viral epitope-specific cytotoxicity T cell response and promotes NK activity 132
Uso di un anticorpo monoclonale antiidiotipo di un anticorpo monoclonale anti-CD4 in pazienti con artrite reumatoide 131
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 131
A sandwich assay to detect and characterize syngeneic anti-idiotypic antibodies to murine anti-HLA and tumor associated antigen monoclonal antibodies 131
Analisi molecolare di un anticorpo monoclonale (ACMO) anti-idiotipo 'immagine interna' dell'antigene CD4 130
Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement 130
Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease 128
CD20 mimicry by mAb Rituximab-specific linear peptide. A potential tool for active immunotherapy of autoimmune diseases 126
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor 125
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 124
Subclinical and clinical atherosclerosis in rheumatoid arthritis: Results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 124
The Fab region of IgG2 human myeloma proteins does not bear the streptococcal protein G-specific determinant 123
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides 122
B-T cell interaction in the pathogenesis of HCV-positive mixed cryoglobulinemia. 121
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 120
Preparation, characterization and utilization of monoclonal antibodies to the gene products of the HLA-D region with special emphasis on those to polymorphic determinants 118
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab 118
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 118
Beta2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 117
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? 117
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 117
Cinetica di produzione e clonotipia di anticorpi anti-anti-idiotipo (Ac3) in due pazienti affette da patologia autoimmune immunizzate con un anticorpo monoclonale anti-idiotipo (AcMo2) 115
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes 115
Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma 115
Anticorpi monoclonali nell'immunoterapia delle malattie autoimmuni 114
Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment 114
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 112
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors 112
Analysis of beta-2 microglobulin (b2M), free HLA class I heavy chain (FHC) and the associated protein pattern in multiple myeloma (MM) patients from the Nordic Myeloma Group Study #5/94. Haematologica-the Hematology Journal 110
The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3) 109
Human anti-mouse antibodies interfere in the determination of sCD4 in intravenous immunoglobulin preparations 108
Syngeneic polyclonal and monoclonal antiidiotypic antibodies to murine anti-human high molecular weight-melanoma associated antigen and anti-HLA monoclonal antibodies 108
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 107
Endothelial cells in tumor microenvironment: insights and perspectives 106
Anti-idiotypic antibodies in therapy: current status and prospects 106
Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile 106
Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA- DR,DP monoclonal antibody CR11-462 105
HLA allele prevalence in disease-modifying antirheumatic drugs-responsive enthesitis and/or arthritis not fulfilling ASAS criteria: Comparison with psoriatic and undifferentiated spondyloarthritis 104
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: Implication for peptide-based active immunotherapy 104
Size variants of beta-2-microglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma 104
Antigenic mimicry by linear peptides of the conformational epitope recognized by the anti-CD20 monoclonal antibody (mAb) Rituximab 103
Analisi della risposta immune indotta da anticorpi monoclonali murini anti-idiotipo (Ab2) anti-CD4 in un sistema xenogenico 103
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count 103
Analysis in a syngeneic and xenogeneic system of mouse antiidiotypic (Ab2) monoclonal antibodies (mAb) elicited with the syngeneic anti-CD4 mAb HP2/6 103
Immunochemical and functional characterization of anti-idiotypic antibodies to a mouse anti-CD4 monoclonal antibody 102
B2 microglobulin-free heavy chain (FHC) of HLA class I antigen in patients with Hodgkin’s and non Hodgkin’s lymphomas 101
Characterization of the specificity of the Human scFv W9 101
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 101
Identificazione del peptide che mima l'epitopo localizzato sulla catena pesante HLA-I non associata alla beta 2-microglobulina, riconosciuto dall'anticorpo monoclonale HC-10 100
Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities 100
Beta2-m-free heavy chain levels of HLA-class I antigen combined with serum IgM or platelet count provide two reliable staging systems in multiple myeloma 100
Analisi della risposta immune indotta da anticorpi monoclonali murini anti-idiotipo (Ab2) anti-CD4 in un sistema xenogenico 100
Anti-idiotypic monoclonal antibodies (mAb) to an anti-CD4 mAb induce CD4+ T cell depletion in rabbit 100
Vaccination against CD20 mimotope peptiide. Is it a feasible strategy for the treatment of autoimmune diseases? 98
Mieloma multiplo e gammapatie monoclonali: quadri clinici, acquisizioni eziopatogenetiche e progressi terapeutici 98
Cloning and chromosomal localization of a cDNA encoding a mitochondrial porin from Drosophila melanogaster 97
An 82-year-old woman with new onset of multiple purple-reddish nodules during treatment with abatacept for rheumatoid arthritis 96
Analisi molecolare di un anticorpo monoclonale (AcMo) anti-idiotipo “immagine interna” dell’antigene CD4 96
Vasculiti primarie sistemiche 96
Anticorpi anti-DNA e network idiotipico nel LES: recenti progressi e prospettive terapeutiche 95
Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate 95
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort 95
Studi in vitro dell'attivita' antiallergica del Fenoterolo 94
Human CD4 "internal antigen" mimicry by anti-idiotypic monoclonal antibodies 94
The proliferative transcriptional factor FOXE3 is the target of anti-CENP-A antibodies (Ab) and identifies a subset of anti-CENP Ab positive systemic sclerosis patients. 93
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 93
Syngeneic anti-idiotypic antisera to murine monoclonal antibodies to monomorphic and polymorphic determinants of HLA class I antigens 92
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification 92
Totale 13.047
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.420
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.415 63 209 8 80 77 70 110 86 63 42 236 371
2022/20232.316 340 204 114 226 323 333 36 264 361 28 52 35
2023/2024856 63 140 43 91 65 221 25 66 6 16 39 81
2024/20253.228 99 48 332 77 68 260 249 281 105 155 479 1.075
2025/20268.084 971 270 398 824 756 414 999 225 1.310 668 200 1.049
2026/2027164 164 0 0 0 0 0 0 0 0 0 0 0
Totale 22.528